{"id":"rbp-7000","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or reaction"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Prolactin elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"RBP-7000 uses Indivior's proprietary RBP (Risperidone Microsphere) technology to deliver risperidone as a long-acting injectable suspension. The microspheres release risperidone gradually over approximately one month, maintaining therapeutic dopamine D2 receptor blockade in the brain. This extended-release formulation improves medication adherence compared to daily oral antipsychotics.","oneSentence":"RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:16.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"}]},"trialDetails":[{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02203838","phase":"PHASE3","title":"Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-06","conditions":"Schizophrenia","enrollment":500},{"nctId":"NCT02687984","phase":"PHASE1","title":"PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2016-02","conditions":"Schizophrenia","enrollment":44},{"nctId":"NCT02768649","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2011-04","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02765555","phase":"PHASE1","title":"First in Man Study of Safety, Tolerability and PK Profile of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2010-03","conditions":"Schizophrenia","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Risperidone","Long-acting Risperidone","risperidone in Atrigel","Risperdal"],"phase":"phase_3","status":"active","brandName":"RBP-7000","genericName":"RBP-7000","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RBP-7000 is a subcutaneous depot formulation of risperidone that provides sustained antipsychotic activity through dopamine D2 receptor antagonism over an extended period. Used for Schizophrenia, Schizoaffective disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}